Table 5 Test's sensitivity according to breast cancer patients’ characteristics
From: Transcutaneous canine breast cancer detection in Tunisia: a pilot study
Factors | Status | sensitivity(%) | P Value |
|---|---|---|---|
Age | – | – | 0,033 |
Menopausal status | Non-menopausal | 79,6 | 0,03 |
Post-menopausal | 82,4 | ||
Diabetes | No | 83,3 | 0,023 |
Yes | 76,5 | ||
Arterial Hypertension | No | 84,7 | 0,023 |
Yes | 71,4 | ||
Dyslipidemia | No | 84,9 | 0,009 |
Yes | 70,4 | ||
Sampling Area | Home | 85,7 | 0,015 |
Hospital | 65,2 | ||
Multifocality | No | 85,8 | 0,459 |
Yes | 79,2 | ||
Tumor size | Small | 80 | 0,275 |
Large | 88 | ||
Metastatic status | Non-metastatic | 82,5 | 0,413 |
Metastatic | 90 | ||
Stage | Early | 76,7 | 0,086 |
Advanced | 89,5 | ||
Histological subtype | Invasive ductal carcinoma | 86 | 0,540 |
Invasive lobular carcinoma | 57,1 | ||
Grade | SBR I—II | 82,8 | 0,666 |
SBR III | 89,5 | ||
Hormone receptors | Negative | 80 | 0,079 |
Positive | 85,1 | ||
Her2neu status | Negative | 88,4 | 0,084 |
Amplified | 74,2 | ||
Delay from chemotherapy | Far from CT courses | 91,4 | 0,018 |
During CT courses | 73,8 |